282 related articles for article (PubMed ID: 18655340)
1. [PSA and hK2 in the diagnosis of prostate cancer].
Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
[TBL] [Abstract][Full Text] [Related]
2. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Becker C; Noldus J; Diamandis E; Lilja H
Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279
[TBL] [Abstract][Full Text] [Related]
3. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
Magklara A; Scorilas A; Catalona WJ; Diamandis EP
Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
[TBL] [Abstract][Full Text] [Related]
4. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
5. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
Lein M; Stephan C; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772
[TBL] [Abstract][Full Text] [Related]
6. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
7. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
[TBL] [Abstract][Full Text] [Related]
8. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen: what's new in 1997.
Pannek J; Partin AW
Oncology (Williston Park); 1997 Sep; 11(9):1273-8; discussion 1279-82. PubMed ID: 9306417
[TBL] [Abstract][Full Text] [Related]
10. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
11. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
12. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
13. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
14. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
[TBL] [Abstract][Full Text] [Related]
15. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
16. [PSA-based parameters].
Nakashima J
Nihon Rinsho; 2005 Feb; 63(2):241-6. PubMed ID: 15714973
[TBL] [Abstract][Full Text] [Related]
17. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
[TBL] [Abstract][Full Text] [Related]
19. Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
Lilja H
Eur Urol; 2001 Apr; 39 Suppl 4():47-8. PubMed ID: 11340291
[No Abstract] [Full Text] [Related]
20. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
